E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia
Prithviraj Bose,Naval Daver,Elias Jabbour,Allison Pike,Kate J. Newberry,Lingsha Zhou,Sherry Pierce,Xuemei Wang,Hagop M. Kantarjian,Srdan Verstovsek +9 more
TL;DR: An ongoing phase-2 study of sotatercept, a first-in-class activin receptor type IIA ligand trap consisting of the extracellular domain of ActIIRA linked to the human IgG1 Fc domain, corrects ineffective erythropoiesis in s-thalassemia and improves erythroid differentiation in persons with lower risk myelodysplastic syndromes.
Journal ArticleDOI
Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Elias Jabbour,Susan O'Brien,Koji Sasaki,Deborah A. Thomas,Guillermo Garcia-Manero,Farhad Ravandi,Gautam Borthakur,Nitin Jain,Marina Konopleva,Jovitta Jacob,Rebecca Garris,Jorge E. Cortes,Hagop M. Kantarjian +12 more
TL;DR: A large number of elderly patients with newly-diagnosed B-cell ALL are eligible for the chemotherapy with mini-hyper-CVD + Inotuzumab ozogamicin, and addition of targeted non-myelosuppressive therapy to effective low-intensity chemotherapy might improve outcome.
Journal ArticleDOI
Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML
Maro Ohanian,Hagop M. Kantarjian,Gautam Borthakur,Tapan M. Kadia,Marina Konopleva,Guillermo Garcia-Manero,Zeev Estrov,Alessandra Ferrajoli,Koichi Takahashi,Elias Jabbour,Naval Daver,Steven M. Kornblau,William G. Wierda,Jan A. Burger,Kiran Naqvi,Christopher B. Benton,Prithviraj Bose,John R. Eckardt,Farhad Ravandi,Jorge E. Cortes +19 more
TL;DR: The first 13 pts with R/R FLT3+ AML treated with salvage idarubicin (Ida) and high-dose ara-C (HiDAC) followed by crenolanib achieved a CR/CRi response and no dose-limiting toxicities were observed at any of the dose levels explored and there were no dose reductions required.
Journal Article
Treatment of relapsed/refractory acute lymphoblastic leukemia.
TL;DR: Binatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL.
Journal ArticleDOI
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
TL;DR: Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy.